Lisata Therapeutics, Inc. · NASDAQ:LSTA
Lisata Therapeutics — NeoStem — Investor Presentation (April 2010)
28 slides from Lisata Therapeutics's investor presentation, Apr 27, 2010
Slide 1: NeoStem, Inc. Investor Presentation
NEOSTEM, INC. (“NBS”) Investor Presentation o? NeeStem: April 2010 WWW.NEOSTEM.COM
Slide 2: Forward-Looking Statements
Forward-Looking Statements Included in this presentation are “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as well as historical information. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, w
Slide 3: Company Overview
Company Overview NeoStem, Inc. (NYSE Amex: NBS) Suzhou Erye — t U.S. Stem Cells China Stem Cells Pharmaceuticals 51% interest acquired October 30, 2009 Ticker NBS (AMEX) 2010 Trading Range $1.26 - $2.15 Market Cap * $86.7 million Corporate Headquarters/ R&D NYC, Boston Subsidiary (location) Suzhou E
Slide 4: Investment Summary
Investment Summary =» Adult stem cell platforms offer high margin, near and long-term revenue opportunities = 2010 launches — orthopedic, anti-aging and cosmetic therapies in PRC and Taiwan = Future — innovative VSEL™ technology therapies for cardiovascular, stroke, wound healing = Leading U.S. prov
Slide 5: Key Company Milestones
Key Company Milestones 2006 - 2008 ¥ Appointed Dr. Robin Smith as CEO (2006) ¥ Purchased NeoStem assets (2006) 4 Acquired world-wide VSEL™ technology license (2007) 4 Received DoD earmark — adult stem cell therapy for wound healing (2008) ¥ Raised ~ $16 million 2009 — 2010 to-date ~/ Commenced opera
Slide 6: Adult Stem Cell Initiatives
Adult Stem Cell Initiatives U.S. & China
Slide 7: Stem Cell Market Opportunity
Stem Cell Market Opportunity Attractive market with both near- and longer-term opportunities = Fragmented market with significant barriers to entry = Commercial opportunities already being realized ex-U.S. = Expedited clinical and regulatory pathways compared to U.S. = Regulated by the Ministry of H
Slide 8: Adult stem cell banking and research
A. Adult stem cell bankin: = Recurring revenue stream = Minimally invasive procedure (“apheresis”) = Growing network in major metropolitan areas = Expand to ten centers by end of 2010 = East and West Coast processing locations through PCT B. Adult stem cell research = Global Research HQ - Cambridge,
Slide 9: Adult Stem Cell Therapies
Adult Stem Cell Thera = Low-dose, short course, GCSF induction of stem cell mobilization = Collection of adult stem cells from peripheral blood of healthy individuals for future use = Process for preparation and storage of collected stem cells = Multiple storage vials containing different stem cell
Slide 10: Launching stem cell therapies in China in 2010
= Leverage platform to begin launching stem cell therapies in China in 2010 = Different clinical/regulatory pathway vs. U.S. — MoH instead of SFDA = More receptive of advanced therapeutics such as stem cell therapy = Broader consumer acceptance of non-traditional therapies = Favorable medical touris
Slide 11: 2010 Targets
2010 Targets = Launch 1st stem cell therapeutic procedure in orthopedics in PRC = Wendeng launched in 1Q — revenue generation to start in 2Q = Open 1st anti-aging & cosmetic treatment center in Taiwan = Enhance to launch adult stem cell collection and storage services in 2Q = Enhance to launch thera
Slide 12: Cord Blood Stem Cell Banking Companies
Cord Blood Stem Cell Banking Companies =) Rl = China Cord Blood (NYSE: CO) »« Acquired by Pantheon China Acquisition Corp. in June 2009 + 9/30/09 LTM revenue = $34.3 million + Current enterprise value = ~$350 million (10.2x LTM revenue) = ViaCell, Inc. « Acquired by PerkinElmer, Inc. in October 2007
Slide 13: Stem Cell Therapeutic Companies
<3 Stem Cell Therapeutic Companies SI Stem Cell Source ALEINGSELE tS) Adult brain tissue Embryonic Mesenchymal System for 4 5 Targeted Segments Collection Therapeutics Therapeutics Targeted Gi hi Ue: US. US. arge’ eographies Euros .S. .S. Other Pharmaceuticals None None Canes (Phase II) LTM Revenue
Slide 14: Pharmaceuticals — China
Pharmaceuticals — China
Slide 15: Large Chinese Pharmaceutical Opportunity
Large Chinese Pharmaceutical Opportunity = China announced $124 billion budget to improve healthcare system in 2009-11 = Provide universal medical service to China’s 1.3 billion population = New Rural & Urban Cooperative Medical Insurance System — at least 90% of population will be covered by 2011 =
Slide 16: Erye — Profitable & Growing
Erye — Profitable & Growing = Vertically-integrated manufacturer of generic antibiotic Rx products and APIs = 7cGMP-certified production lines =» Extensive distribution network covering all of PRC = No significant customer concentration 60% of current drug portfolio covered by insurance (expected to
Slide 17: Erye — Diversified Product Portfolio
Erye — Diversified Product Portfolio No single drug accounting for >10% of sales Top Ten Drugs in 2009 (52.6% of Total Sales) Drugs % of Sales Acetylspiramycin 75% Oxacillin Sodium 7.2% Mezlocillin Sodium for injection 6.9% Amoxicillin Sodium & Sulbactam Sodium for injection 6.5% Cefoperazone Sodium
Slide 18: New facility completed in 2009
= New facility completed in 2009 = Penicillin sterile API facility for solvent crystallization and freeze dried raw material drugs with two cGMP lines approved = 2010 / 2011 targets = Penicillin powder for injection facility = Cephalosporin powder for injection facility = Oral API facility = Freeze
Slide 19: Platform to Drive Growth
— Platform to Dr = Current pipeline of 7 Rx drugs — two approved, two pending SFDA approval = Growth strategy = Enhance R & D acti ies in China and the U.S. = In-license drugs with proven efficacy & efficacy that leverages new facility = Expand indications beyond anti-infectives peline Drugs Form/Do
Slide 20: Chinese Pharmaceutical Companies
Chinese Pharmaceutical Companies (Sin millions, except per share data and multiples) Price Revs (M) Ev/Rev PIE icker04/07/10 LTM FY10E LTM FY10 LTM FY10E LTM FY10E Company Name 3 SBio SSRX $1134 $46 $58 53x 4.2x $0.56 $0.63 203x 18.0x American Oriental Bioengineering AOB $4.15 $296 $329 12x 11x $0.5
Slide 21: Equity Structure
Equity Structure
Slide 22: Management & Directors (Excluding RimAsia)
Management & Directors (Excluding RimAsia) EET /Fullbright (Erye Managers and Minority Interest Holder) RimAsia Enhance Biomedical Holdings (Strategic Partner) Public / Other % ‘% Based on SEC Outstanding | Benefici 5.1% 7.8% 30.3% 9.1% AT1% Capitalization (Common Share Equivalent in 000s) Shares Ou
Slide 23: Management and Boards
Management and Boards
Slide 24: Key Executives
Key Executives Robin Smith, MDMBA = _-MD— Yale; MBA— Wharton CEO & Chairman ofthe = Formerly President & CEO IP2M (HC multimedia), EVP & CMO HealthHelp (radiology management) Board « Trustee of NYU Medical Center, Chairman of the Board of NYU Hospital for Joint Diseases (through November 2008) and S
Slide 25: Board of Directors
Board of Directors Robin Smith, MD, MBA CEO and Chairman Eric Wei = BS Mathematics & Economics — Amherst College; MBA — Wharton Managing Partner, = Experience — Founder/Managing Partner of RimAsia Capital Partners (private equity); RimAsia Capital Partners Peregrine Capital, Prudential Securities, L
Slide 26: Scientific Advisory Board Members
‘y Board Members Wayne Marasco, «Associate Professor, Dept of Cancer and Immunology & AIDS at Dana-Farber Cancer Institute; Mp, PhD Associate Professor of Medicine at Harvard Medical School (Chairman) = Leading NeoStem’s independent research efforts and collaborations Douglas Losordo, = Director of
Slide 27: Contact Information
Contact Information NeoStem, Inc. Robin Smith, MD, MBA Chairman & CEO Phone: (212) 584-4174 Email: rsmith@neostem.com http://www.neostem.com CCG Investor Relations, Inc. Lei Huang Account Manager Phone: (646) 833-3417 (New York) Email: lei.huang@ccgir.com http://www.ccgir.com Crocker Coulson Preside
Slide 28: NeoStem, Inc.
NEOSTEM, INC. (“NBS”) Investor Presentation WWW.NEOSTEM.COM